Chapter Two - Extracellular vesicles: Potential impact on cardiovascular diseases
Introduction
Cardiovascular diseases (CVD), including coronary heart disease, heart failure, stroke, congenital heart disease, rhythm disorders, and hypertension, remain the leading causes of morbidity and mortality around the world [1]. In the United States, the prevalence of CVD in adults 20 years of age and older is 48.0% overall (121.5 million in 2016) (NHANES 2013–2016) [2]. The prevalence of CVD increases with age in both males and females. In 2016, approximately 161,438 (19.2%) Americans who were < 65 years old died of CVD; 306,638 (36.5%) of the deaths attributable to CVD occurred before the age of 75 years [2]. In 2016, the Chinese Cardiovascular Disease Report estimated that 290 million (21%) Chinese had CVD, the leading cause of mortality (61%) [3]. Globally, CVD produces immense health and economic burden [4], [5], [6]. In the United States, the cost of informal caregiving for patients with CVD is projected to increase from $616 billion in 2015 to $1.2 trillion in 2035 [7]. Thus, increasing the efficacy in the prevention and treatment of CVD has a huge potential in improving global health outcome and decreasing financial burden [8], [9].
Cell-to-cell communication, a key process in multicellular organisms, is required to guarantee proper coordination among the different cell types within tissues and thus, fundamental for the functioning of biological systems. There are multiple modes of intercellular communication, including soluble factors, tunneling nanotubes, and extracellular vesicles (EVs), which allow the transfer of surface molecules or cytoplasmic components from one cell to another [10], [11], [12]. Among them, EVs have received a lot of attention in biological and clinical research due to their ability to mediate cell-cell crosstalk. EVs originate from diverse subcellular compartments of most eukaryotic cells and are released into the extracellular space in normal and disease states [13], [14], [15]. EVs are categorized as exosomes, microvesicles, and apoptotic bodies, according to their abundance, size, and composition. They contain different materials, which include many functional molecules, such as microRNAs (miRNAs), messenger RNAs (mRNAs), long non-coding RNAs (lncRNAs), proteins, DNA fragments, and lipids [12], [13], [14]. Those components can be delivered from the cell of origin to a recipient cell, whether the recipient cell is in the vicinity or distant from the cell of origin. The transferred molecules are potentially capable of eliciting changes in function and gene expression in the recipient cell. Numerous studies have shown that EVs may serve as biomarkers for the diagnosis and treatment of diseases, including cardiovascular diseases [16], [17], [18]. In this review, we discuss the evolving understanding of the role of EVs in CVD, summarize the current knowledge of EV-mediated regulatory mechanisms, and highlight potential strategies for the diagnosis and treatment of CVD, and also attempt a look into the future. These may advance our understanding of the role of EVs in CVD and provide novel insights into the field of translational medicine.
EVs were first described in 1967; this subcellular fraction, identified by electron microscopy, consists of small vesicles, with a diameter between 20 and 50 nm, and termed “platelet dust” from activated platelets [19]. EV is an umbrella term for all types of vesicles released from prokaryotic and eukaryotic cells. Currently, there is an ongoing debate on the classification of EVs with some investigators having preference to classify the EVs according to their source, such as endothelial cell-derived EVs, vascular smooth muscle cell-derived EVs, cardiac fibroblast-derived EVs, macrophage-derived EVs, etc. [20], [21], [22]. However, this manner of classification for EVs does not reflect the character of a particular EV. Moreover, there is also some controversy on the nomenclature and sizes of the different types of vesicles. Therefore, in 2014 and updated in 2018, the International Society for Extracellular Vesicles (ISEV) provided some standards in the classification of EVs, based on various morphological, biochemical, and biogenic parameters [23], [24]. However, until now, there is no consensus on the nomenclature of EVs that define the cellular origin or classification of EVs once they have been secreted or shed from the cell of origin [25]. For this reason, the term “extracellular vesicle” is suggested by the ISEV as a generic name for all secreted vesicles, and also as a keyword in publications [26]. Recent reviews have categorized EVs into three groups [27], [28], [29]: exosomes, microvesicles, and apoptotic bodies.
Exosomes are a homogenous population of EVs derived from the endocytic compartment. These cell-derived nanovesicles, ranging in size between 30 and 100 nm in diameter, are surrounded by a lipid bilayer [30], [31]. Usually, exosomes are able to float on a sucrose gradient at a density of 1.13–1.19 g/mL. Exosomes typically display a cup-like shape when observed by transmission electron microscopy, but this may be an artifact [32]. Their biogenesis is initiated by the inward budding of multi-vesicular endosomes. The transmembrane proteins are endocytosed and trafficked to early endosomes, which invaginate to generate intraluminal vesicles and form multivesicular bodies (MVBs). Then, the MVBs can either fuse with the plasma membrane and the intraluminal vehicles are released as exosomes into the extracellular space (Fig. 1); the intraluminal vesicles can also fuse with lysosomes for eventual degradation [33], [34].
Exosomes are released from cells via a constitutive or inducible mechanism, depending on the cell type of origin [35]. In general, exosomes are wrapped by a phospholipid bilayer, enriched with sphingomyelin, ceramide, and cholesterol [36], [37]. The biochemical composition of exosomes depends on the cell source. Cells release subpopulations of exosomes with different sizes, compositions, and molecular and biological properties [38]. The mechanisms proposed for their release, include Rab GTPases (Rab11/35, Rab27), tetraspanins, and SNAREs (soluble N-ethylmaleimide-sensitive attachment protein receptors) complex [39], [40], [41]. Tetraspanins, including CD9, CD63, CD81, CD82, and CD151, exist in released exosomes and accumulate in plasma membrane endosomes and microdomains [42], [43]. In the plasma membrane, tetraspanins form tetraspanin-enriched microdomains (TEMs). TEMs are involved in many biological process, including exosome biogenesis, exosome internalization, selection of exosome cargo, and antigen presentation [44], [45]. In addition to tetraspanins and lipids, there are other components, such as cargos, in EVs, including sorting proteins (e.g., Alix, clathrin, TSG101), related to MVB biogenesis, membrane proteins (e.g., Rab GTPase and annexins) regulating exosome docking and membrane fusion, cytoskeleton proteins (e.g., actin, tubulin), inflammatory cytokines (e.g., IL-10, transforming growth factor-β [TGF-β]), metabolic enzymes (e.g., pyruvate kinase, α-enolase), as well as different RNA species (e.g., mRNA, miRNA, lncRNA), and DNAs [12], [13], [14], [46], [47]. Via the above cargos, exosomes can exert their vast and varied physiological functions, through either direct interaction with surrounding cells, where they are generated, or transported to distant recipient cells by their release into the circulatory fluid system.
Microvesicles, also known as microparticles, ectosomes, and membrane particles, represent a more heterogeneous population than exosomes. They are a class of EVs typically ranging in size between 100 and 1000 nm in diameter [48], [49]. Although exosomes are generally smaller than microvesicles, their sizes may overlap. Microvesicles float on sucrose gradient at a density of 1.04–1.07 g/mL. They have been characterized predominantly, as products of platelets, red blood cells, and endothelial cells.
In addition to the size and density differences, microvesicles differ from exosomes by their mechanisms of release and biogenesis. Microvesicles are derived from activated or apoptotic cells through outward budding and fission of membrane vesicles from the plasma membrane [50], [51]. In response to stimuli, outward blebbing may be dependent on various enzymes and mitochondrial or calcium signaling. Microvesicle shedding shares a similar process with virus budding. Moreover, microvesicles may be assembled selectively in the lipid-rich microdomains of the membrane, including lipid rafts or caveolae [52], [53]. In mammals, microvesicles are released from almost all cell types, including blood cells (e.g., platelets, erythrocytes, leukocytes), vascular smooth muscle cells (VSMCs), and endothelial cells [54], [55], [56]. The release can be observed within a few seconds after stimulation [41].
Microvesicles reflect the nature and the activation state of the parent cell and are identified by the expression of phosphatidylserine on their surfaces, which is indicative of their release from apoptotic or activated cells. The preferential binding of annexin to phosphatidylserine can be used to detect the exposed phosphatidylserine on the surface of apoptotic cells and phosphatidylserine-positive microvesicles subclass [57], [58]. However, not all microvesicles express phosphatidylserine, and therefore, certain microvesicle populations fail to bind annexin V [59], suggesting that some microvesicles might be formed by other undetermined mechanisms. Microvesicles have markers different from those of exosomes, e.g., tryptophanyl-TRNA synthase 1 and C1q [41]. It should be noted that there are some similarities between exosomes and microvesicles. For example, both contain adhesion molecules, membrane receptors, tissue factors, cytoskeletal proteins, chemokines, various enzymes and cytokines, as well as DNAs and RNAs (mRNA, microRNA). Microvesicles can carry nuclear proteins that originate from apoptotic cells [60], [61].
Apoptotic bodies, generally ranging in size from 1 to 5 μM in diameter (approximately the size of platelets), are produced from the plasma membrane as blebs when cells undergo apoptosis. Apoptotic bodies are closed structures and are larger than exosomes and microvesicles. They float on a sucrose gradient at a density between 1.16 and 1.28 g/mL, overlapping with the density of exosomes. Apoptotic membrane blebbing is a late stage of programmed cell death that is controlled by caspase-mediated cleavage, and subsequent activation of Rho-associated protein kinases [62], [63]. They are characterized by the presence of externalized phosphatidylserine and permeable membrane. Apoptotic bodies contain several intracellular fragments and cellular organelles, including histones, DNA fragments, degraded proteins, nuclear fractions, coding RNAs, noncoding RNAs, and DNAs, similar to those inside microvesicles [62], [63], [64], [65].
Apoptotic bodies may provide an easier system for cellular clearance, since they are smaller than cells and are, therefore, easier to phagocytose [66]. Apoptotic bodies have been suggested to act by “dispatching suicide notes” on the surrounding environment. Indeed, apoptotic body membranes show increased permeabilization by releasing proteins into the microenvironment during the early stages of apoptosis. In turn, the surrounding cells, which lose their membrane integrity, affect apoptotic cells during secondary necrosis [67]. However, the exact function of apoptotic bodies is still unclear. Moreover, little is known about their molecular composition. Therefore, the role of apoptotic bodies in the pathophysiology of disease is not covered in this review.
As stated above, because of the difficulties in the isolation and detection of EVs, their classification cannot be rigorously determined in most settings at this time. The ISEV has provided some standards to classify EVs, according to various morphological, biochemical, and biogenic parameters. EVs continue to be classified into exosomes, microvesicles, and apoptotic bodies [27], [28], [29]. With the improvement of technologies, more criteria for the classification for EVs could be added, such as refractive index, potential energy, and chemical composition [68], [69].
The isolation and purification of EVs have attracted attention because of their potential to aid in the diagnosis and treatment of a broad range of disorders. Today, diverse biochemical and biophysical properties of EVs are used in their isolation, including buoyant density, size, shape, charge, and surface composition [24], [70], [71], [72]. The most widely used method for EV isolation is differential centrifugation, originally developed by Johnstone et al. for the separation of EVs in reticulocyte tissue culture fluid and subsequently optimized by Théry et al. [32], [73]. Differential centrifugation can separate vesicle particles based on their size and density by sequentially increasing the centrifugal force to pellet cells and debris (< 1500 g), large EVs (10,000–20,000 g), and small EVs (100,000–200,000 g) [74]. This method is widely used for various biological samples and is considered the standard for isolating EVs.
In addition to differential centrifugation, other methods have been developed for the isolation of EVs. These include density gradient centrifugation, size-exclusion chromatography, ultrafiltration, immunocapture, and various precipitation-based methodologies, using different reagents [24], [75]. In theory, EVs may be isolated based solely on their physicochemical properties, because they are larger than protein fractions but smaller than whole cells, more dense than the lipid fractions, and have a defined density range [76]. However, the above methods have not reached the ultimate goal of having homogeneous EV subpopulations and precise study of their targets. All of these approaches have their respective limitations, which should be taken into consideration; technical standards are not yet fully established [77]. Some researchers have proposed that the choice of a specific isolation method may depend not only on the type of sample (for example, proteinuric urine or non-proteinuric urine) but also on the type of downstream analyses used for “omics” characterization (e.g., transcriptomics or proteomics) [28]. Furthermore, currently, most researchers perform one or more other methods after the main steps, such as washing in EV-free buffer, ultrafiltration, and further purification by density gradient [78]. Thus, currently, there is no ideal method to isolate relatively pure samples that only contain EVs. Further improvements of the above or new methods to isolate EVs are needed.
Section snippets
Biological functions of EVs
Initially, EVs were thought to be merely inert cellular debris, also known as “cell dust,” with no biological significance. However, subsequent studies indicated that EVs play important roles in the regulation of a wide range of normal cellular physiological processes, such as waste scavenging, cellular stress reduction, intercellular communication, immune regulation, and cellular homeostasis modulation.
EVs and cardiovascular diseases
As mentioned above, EVs are involved in physiological processes that are associated with intercellular communication. In the cardiovascular system, EVs could be produced by a variety of cells such as cardiomyocytes, VSMCs, endothelial cells, fibroblasts, immune cells, platelets, leukocytes, and erythrocytes [137]. These EVs have been found to play vital roles in both cardiovascular physiological and pathological conditions, which involve the modulation of specific receptor or signal
Levels of EVs in diagnostic or prognostic potential of CVDs
Numbers of studies have shown that EVs derived from different origins such as platelets, erythrocytes, leukocyte, and endothelial cells may be considered as valuable markers for the diagnosis or prognosis of CVDs [185], [234], [272]. Until now, most of the studies showed increased EV levels in the circulating of patients with CVDs. For example, microparticles from red blood cells have been shown to be increased in STEMI; moreover, erythrocyte microparticles are related to the output of creatine
Conclusion and perspective
In summary, many studies have highlighted the contribution of EVs in the regulation of a wide range of normal cellular physiological processes, including waste scavenging, cellular stress reduction, intercellular communication, immune regulation, and cellular homeostasis modulation (Fig. 2). EVs play vital roles in both cardiovascular physiological and pathological processes. Depending upon the cell type of origin, EVs can contribute to the pathophysiological development and progression of
Acknowledgments
These studies were supported, in part, by grants from the National Natural Science Foundation of China (31730043, 81770425), National Key R&D Program of China (2018YFC1312700), Program of Innovative Research Team by National Natural Science Foundation (81721001), Grant from The Third Affiliated Hospital of Chongqing Medical University (KY19024), and the National Institutes of Health, USA (R01 DK039308, DK119652, and P01 HL074940).
Conflict of interest
The authors declare that they have no competing interests. This manuscript is an original contribution, not previously published, and not under consideration for publication elsewhere.
References (306)
Epidemiology of cardiovascular disease in China: current features and implications
Nat. Rev. Cardiol.
(2019)Reducing the cardiovascular disease burden for people of all ages in the Americas region: analysis of mortality data, 2000-15
Lancet Glob. Health
(2019)- et al.
Extracellular vesicles: novel mediators of cell communication in metabolic disease
Trends Endocrinol. Metab.
(2017) - et al.
Exosomal non-coding RNAs (Exo-ncRNAs) in cardiovascular health
J. Mol. Cell. Cardiol.
(2019) The secret life of exosomes: what bees can teach us about next-generation therapeutics
J. Am. Coll. Cardiol.
(2018)Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers
Eur. J. Cancer
(2017)- et al.
Ectosomes and exosomes: shedding the confusion between extracellular vesicles
Trends Cell Biol.
(2015) Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling
Blood
(2015)Hyperbaric oxygen boosts long noncoding RNA MALAT1 exosome secretion to suppress microRNA-92a expression in therapeutic angiogenesis
Int. J. Cardiol.
(2019)Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation
Blood
(2005)
Leukocyte-derived microvesicles dock on glomerular endothelial cells: stardust in the kidney
Kidney Int.
Inflamed macrophage microvesicles induce insulin resistance in human adipocytes
Nutr. Metab. (Lond.)
Rho kinase regulates fragmentation and phagocytosis of apoptotic cells
Exp. Cell Res.
The Extracellular RNA Communication Consortium: establishing foundational knowledge and technologies for extracellular RNA research
Cell
Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes)
J. Biol. Chem.
Recent developments in the nomenclature, presence, isolation, detection and clinical impact of extracellular vesicles
J. Thromb. Haemost.
Exfoliation of membrane ecto-enzymes in the form of micro-vesicles
Biochim. Biophys. Acta
Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor
Cell
Exosomes from adipose-derived mesenchymal stem cells prevent cardiomyocyte apoptosis induced by oxidative stress
Cell Death Dis.
miR-93-5p-containing exosomes treatment attenuates acute myocardial infarction-induced myocardial damage
Mol. Ther. Nucleic Acids
Macrophage-derived mir-155-containing exosomes suppress fibroblast proliferation and promote fibroblast inflammation during cardiac injury
Mol. Ther.
Mesenchymal stem cells-derived extracellular vesicles, via miR-210, improve infarcted cardiac function by promotion of angiogenesis
Biochim. Biophys. Acta. Mol. Basis Dis.
Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association
Circulation
Heart disease and stroke statistics-2019 update: a report from the American Heart Association
Circulation
Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden
Nat. Rev. Cardiol.
Cardiovascular disease in Africa: epidemiological profile and challenges
Nat. Rev. Cardiol.
The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review
BMC Public Health
Projected costs of informal caregiving for cardiovascular disease: 2015 to 2035: a policy statement from the American Heart Association
Circulation
Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease
Circ. Res.
Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Nat. Chem. Biol.
Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication
Nat. Cell Biol.
Circulating extracellular vesicles in human disease
N. Engl. J. Med.
Extracellular vesicles: mechanisms in human health and disease
Antioxid. Redox Signal.
Extracellular vesicles in cancer—implications for future improvements in cancer care
Nat. Rev. Clin. Oncol.
Coronary artery-bypass-graft surgery increases the plasma concentration of exosomes carrying a cargo of cardiac microRNAs: an example of exosome trafficking out of the human heart with potential for cardiac biomarker discovery
PLoS One
Diagnostic tools for hypertension and salt sensitivity testing
Curr. Opin. Nephrol. Hypertens.
Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy
J. Clin. Invest.
The nature and significance of platelet products in human plasma
Br. J. Haematol.
PDGF-BB carried by endothelial cell-derived extracellular vesicles reduces vascular smooth muscle cell apoptosis in diabetes
Diabetes
microRNA-423-3p exosomes derived from cardiac fibroblasts mediates the cardioprotective effects of ischaemic post-conditioning
Cardiovasc. Res.
Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity
Cell
Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles
J. Extracell. Vesicles
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
J. Extracell. Vesicles
Standardization of sample collection, isolation and analysis methods in extracellular vesicle research
J. Extracell. Vesicles
As we wait: coping with an imperfect nomenclature for extracellular vesicles
J. Extracell. Vesicles
Extracellular vesicles and the application of system biology and computational modeling in cardiac repair
Circ. Res.
Isolation and characterization of urinary extracellular vesicles: implications for biomarker discovery
Nat. Rev. Nephrol.
The biology and function of exosomes in cancer
J. Clin. Invest.
Isolation and characterization of exosomes from cell culture supernatants and biological fluids
Curr. Protoc. Cell Biol.
Exosomes or microvesicles, a secreted subcellular organelle contributing to inflammation and diabetes
Diabetes
Cited by (10)
Density-based lipoprotein depletion improves extracellular vesicle isolation and functional analysis
2024, Journal of Thrombosis and HaemostasisApplying proteomics in metabolic dysfunction-associated steatotic liver disease: From mechanism to biomarkers
2023, Clinics and Research in Hepatology and GastroenterologyStatus quo of Extracellular Vesicle isolation and detection methods for clinical utility
2023, Seminars in Cancer BiologyCitation Excerpt :Biogenesis relies on trafficking of genetic cargo to the membrane, redistribution of membrane phospholipids and actomyosin contractility for ectocytosis-based release [67]. Microvesicles typically have a density of 1.03-1.2 g/mL [68–72] and are often characterised by expression of Annexin A1 [69, 73], CD40 [74, 75], integrin-β [74, 76] and selectins [42, 77–79]. However, microvesicles spill over into the size range of LEVs, thus can be detected in both EV populations (Fig. 1).
Mesenchymal Stem Cells in the Pathogenesis and Therapy of Autoimmune and Autoinflammatory Diseases
2023, International Journal of Molecular Sciences